Project Oncology®

177 Épisodes

1. Managing Immune-Related Adverse Events With Immunotherapies

   Publié: 03/05/2024
2. Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens

   Publié: 03/05/2024
3. The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence

   Publié: 03/05/2024
4. Overcoming Barriers to Equitable Care in HNSCC

   Publié: 03/05/2024
5. Indications to Switch Therapies for Myelofibrosis Patients

   Publié: 23/04/2024
6. Managing Myelofibrosis with a Patient-Centered Approach

   Publié: 17/04/2024
7. Exploring the Significant Presence of Anemia in Myelofibrosis

   Publié: 15/04/2024
8. Anemia and Myelofibrosis: Optimizing Diagnosis, Treatment, and Management Strategies

   Publié: 15/04/2024
9. Navigating Myelofibrosis Treatment Complexities to Optimize Care

   Publié: 09/04/2024
10. Maximizing B-Cell Lymphoma Outcomes with CAR T-Cell Therapy and Personalized Care

    Publié: 04/04/2024
11. Managing B-Cell Lymphomas in the Second-Line Setting: The Role of CAR T-Cell Therapy

    Publié: 04/04/2024
12. B-Cell Lymphoma Care: Overcoming Challenges in the Second-Line Setting

    Publié: 04/04/2024
13. Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights

    Publié: 13/03/2024
14. mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib

    Publié: 20/02/2024
15. Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access

    Publié: 15/02/2024
16. Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification

    Publié: 09/02/2024
17. Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care

    Publié: 09/02/2024
18. The Necessity of a Multidisciplinary Approach Through the mCRPC Treatment Journey

    Publié: 29/01/2024
19. Emerging Strategies in Multi-Cancer Early Detection

    Publié: 29/01/2024
20. Treating High-Risk Biochemically Recurrent Prostate Cancer: An Update from ASCO-GU

    Publié: 25/01/2024